Global pharmaceutical company Allergan, an AbbVie company, has entered an agreement with privately owned aesthetics company Luminera.
The agreement means that Allergan will acquireitsfull dermal filler portfolio including HArmonyCa, a dermal filler intended for facial soft tissue augmentation which comprises a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres.
The Luminera dermal filler portfolio also includes a line of HA dermal fillers, as well CaHA-based fillers commercialised across several markets. Brands include Crystalys, Hydryalix and Hydryal.
Luminera chairman Dadi Segal commented, “We believe bringing together key, innovative Luminera assets with the support of Allergan Aesthetics will provide an even brighter future for our people, products and a more expanded offering for our customers. This is a tremendous opportunity to further build, develop and collaborate with a leading global aesthetics company.”
